The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday. The drug will likely dominate ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

According to estimates form the U.S. Food and Drug Administration (FDA), 40 million men and 20 million women experience hair loss. In 2003, 31,737 people, 88% of them men, underwent hair ...